Pembrolizumab Plus Chemotherapy for HR+/HER2− PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426080774?dgcid=rss_sd_all
Pembrolizumab Plus Chemotherapy for HR+/HER2− PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426080774?dgcid=rss_sd_all
“Pembrolizumab Plus Chemotherapy for HR+/HER2− PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.” Annals of Oncology.
@article{article36276,
title = {Pembrolizumab Plus Chemotherapy for HR+/HER2− PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426080774?dgcid=rss_sd_all}
}